Research progress of mesenchymal stem cell in treating anal fistula in Crohn's disease
-
摘要: 克罗恩病(Crohn's disease，CD)是一种累及全消化道的跳跃性全层炎症性肠病，肛瘘是CD常见的临床表现之一，临床发病率可达28%~43%。CD肛瘘的治疗需要结合患者的实际情况选择个体化的治疗方案，包括合适的药物种类和手术方法，目前并没有高成功率的金标准治疗方案，临床复发率较高。间充质干细胞(mesenchymal stem cell，MSC)是一种多能干细胞，具有自我更新和分化为多种类型细胞的能力，被广泛应用于再生医学领域，MSC疗法对于CD患者是一种富有前景的新选择。与传统治疗手段相比，MSC在诱导和维持瘘管闭合方面表现出更高的效率，具有很强的免疫调节作用和微创性，特别是对于瘘管复杂、常规治疗不耐受的患者。本文结合国内外最新研究报道，就MSC治疗CD肛瘘的研究进展进行综述。Abstract: Crohn's disease (CD) is a leaping full-layer inflammatory bowel disease involving the whole digestive tract. Anal fistula is one of the common clinical manifestations CD, with a clinical incidence of 28%-43%. The treatment of CD anal fistula needs to be combined with the actual situation of the patient to select an individualized treatment plan, including appropriate drug types and surgical methods. Currently, there is no gold standard treatment plan with a high success rate, and the clinical recurrence rate is high. Mesenchymal stem cells (MSC) are pluripotent stem cells that have the ability to self-renew and differentiate into multiple cell types and are widely used in the field of regenerative medicine. MSC therapy is a promising new treatment option for patients with CD. Compared with traditional treatments, MSC showed higher efficiency in inducing and maintaining fistula closure, and had a strong immunomodulatory effect and was minimally invasive. Especially for patients with complex fistulas that are intolerant to conventional treatment. Based on the latest research reports at home and abroad, this article reviews the research progress of MSC in treating anal fistula in CD.
-
Key words:
- Crohn's disease /
- anal fistula /
- mesenchymal stem cell /
- surgical treatment
-
-
[1] Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn'sdisease: the Toronto consensus[J]. Inflamm Bowel Dis, 2019, 25(1): 1-13. doi: 10.1093/ibd/izy247
[2] Yamamoto T, Nakase H, Watanabe K, et al. Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn's disease: subgroup analysis from inception cohort registry study of patients with Crohn'sdisease(iCREST-CD)[J]. J Crohns Colitis, 2023, 17(8): 1193-1206. doi: 10.1093/ecco-jcc/jjad038
[3] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0
[4] Aniwan S, Santiago P, Loftus Jr EV, et al. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries[J]. United European Gastroenterol J, 2022, 10(10): 1063-1076. doi: 10.1002/ueg2.12350
[5] Hong L, Zhang C, Fan R, et al. Infliximab for Crohn's Disease Patients with Perianal Fistulas: Better Image, Better Life[J]. Med Sci Monit, 2020, 26: e925018-1.
[6] Rizzo G, Rubbino F, Elangovan S, et al. Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(3): 741-764. doi: 10.1016/j.jcmgh.2022.12.006
[7] Tozer PJ, Lung P, Lobo AJ, et al. Pathogenesis of Crohn's perianal fistula-understanding factors impacting on success and failure of treatment strategies[J]. Aliment Pharmacol Ther, 2018, 48(3): 260-269. doi: 10.1111/apt.14814
[8] Cao S, Colonna M, Deepak P. Pathogenesis of perianal fistulising Crohn's disease: current knowledge, gaps in understanding, and future research directions[J]. J Crohns Colitis, 2023, 17(6): 1010-1022. doi: 10.1093/ecco-jcc/jjad008
[9] Cao D, Qian K, Zhao Y, et al. Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn's Disease[J]. J Crohns Colitis, 2023, 17(4): 580-592. doi: 10.1093/ecco-jcc/jjac171
[10] Geldof J, Iqbal N, LeBlanc JF, et al. Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials[J]. Lancet Gastroenterol Hepatol, 2022, 7(6): 576-584. doi: 10.1016/S2468-1253(22)00007-3
[11] Reginelli A, Vacca G, Giovine S, et al. MRI of perianal fistulas in Crohn's disease[J]. Acta Biomed, 2020, 91(8-S): 27-33.
[12] Jeri-McFarlane S, Garcia-Granero A, OchogavIa-Segui A, et al. Three-dimensional modelling as a novel interactive tool for preoperative planning for complex perianal fistulas in Crohn's disease[J]. Int J Colorectal Dis, 2023, 25(6): 1279-1284. doi: 10.1111/codi.16539
[13] 倪耿欢, 赵宏伟, 亓昌珍, 等. 克罗恩病肛瘘与非克罗恩病肛瘘的MRI特征对比分析[J]. 中华放射学杂志, 2019, 53(4): 305-309.
[14] 陈鹏, 张加敏, 马嘉泽, 等. 肛周局部处理方案在克罗恩病肛瘘治疗中的研究进展[J]. 国际医药卫生导报, 2021, 27(1): 11-16. doi: 10.3760/cma.j.issn.1007-1245.2021.01.003
[15] Shen B, Kochhar GS, Rubin DT, et al. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International leal Pouch Consortium[J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 69-95. doi: 10.1016/S2468-1253(21)00214-4
[16] Barreiro-de Acosta M, Fernandez-Clotet A, Mesonero F, et al. Long-term outcomes of biological therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU[J]. Am J Gastroenterol, 2023, 118(6): 1036-1046. doi: 10.14309/ajg.0000000000002152
[17] Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn's disease, seton versus anti-TNF versus surgical closure following anti-TNF[PISA]: a randomised controlled trial[J]. J Crohns Colitis, 2020, 14(8): 1049-1056. doi: 10.1093/ecco-jcc/jjaa004
[18] van Praag EM, Stellingwerf ME, van der Bilt JDW, et al. Ligation of the intersphincteric fistula tract and endorectal advancement flap for high perianal fistulas in Crohn's disease: a retrospective cohort study[J]. J Crohns Colitis, 2020, 14(6): 757-763. doi: 10.1093/ecco-jcc/jjz181
[19] Meima-van Praag EM, van Rijn KL, Wasmann KA, et al. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease(PISA-Ⅱ): a patient preference randomised trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(7): 617-626. doi: 10.1016/S2468-1253(22)00088-7
[20] Brochard C, Landemaine A, L'Heritier AM, et al. Anal fistulas in severe perineal Crohn's disease: MRI assessment in the determination of long-term healing rates[J]. Inflamm Bowel Dis, 2018, 24(7): 1612-1618. doi: 10.1093/ibd/izy055
[21] Nazari H, Naei VY, Tabasi AH, et al. Advanced regenerative medicine strategies for treatment of perianal fistula in Crohn's disease[J]. Inflamm Bowel Dis, 2022, 28(1): 133-142. doi: 10.1093/ibd/izab151
[22] El-Nakeep S. Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes[J]. Curr Stem Cell Res Ther, 2022, 17(8): 727-733. doi: 10.2174/1574888X16666210910112403
[23] 宫东伟, 邢贻雷, 王开琼, 等. 骨形态发生蛋白-2调控MAPK信号通路在肝癌干细胞特征维持中的机制研究[J]. 中国中西医结合消化杂志, 2022, 30(8): 573-578, 590. doi: 10.3969/j.issn.1671-038X.2022.08.06
[24] Wiodarczyk M, Czerwinska K, Wiodarczyk J, et al. Current overview on the use of mesenchymal stem cells for perianal fistula treatment in patients with Crohn's disease[J]. Life(Basel), 2021, 11(11): 1133.
[25] Sengun E, Wolfs TGAM, van Bruggen VLE, et al. Umbilical cord-mesenchymal stem cells induce a memory phenotype in CD4+ T cells[J]. Front Immunol, 2023, 14: 1128359. doi: 10.3389/fimmu.2023.1128359
[26] Liu Y, Zhang M, Li J, et al. Human umbilical cord mesenchymal stem cell-derived exosomes promote murine skin wound healing by neutrophil and macrophage modulations revealed by single-cell RNA sequencing[J]. Front Immunol, 2023, 14: 1142088. doi: 10.3389/fimmu.2023.1142088
[27] Zhang HM, Yuan S, Meng H, et al. Stem cell-based therapies for inflammatory bowel disease[J]. Int J Mol Sci, 2022, 23(15): 8494. doi: 10.3390/ijms23158494
[28] Zhang W, Ling Y, Sun Y, et al. Extracellular Vesicles Derived from Mesenchymal Stem Cells Promote Wound Healing and Skin Regeneration by Modulating Multiple Cellular Changes: A Brief Review[J]. Genes(Basel), 2023, 14(8): 1516.
[29] Wang H, Jiang HY, Zhang YX, et al. Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials[J]. Stem Cell Res Ther, 2023, 14(1): 103. doi: 10.1186/s13287-023-03331-6
[30] Sorensen KM, Jensen CH, Sheikh SP, et al. Treatment of fistulizing perianal crohn's disease by autologous microfat enriched with adipose-derived regenerative cells[J]. Inflamm Bowel Dis, 2022, 28(6): 967-970. doi: 10.1093/ibd/izab276
[31] Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel(mesenchymal stem cell treatment)in patients with perianal fistulizing Crohn's disease: ADMIRE-CD phase 3 randomized controlled trial[J]. Dis Colon Rectum, 2022, 65(5): 713-720. doi: 10.1097/DCR.0000000000002325
[32] Furukawa S, Mizushima T, Nakaya R, et al. Darvadstrocel for complex perianal fistulas in Japanese adults with Crohn's disease: a phase 3 study[J]. J Crohns Colitis, 2023, 17(3): 369-378. doi: 10.1093/ecco-jcc/jjac144
[33] Dozois EJ, Lightner AL, Dietz AB, et al. Durable Response in Patients With Refractory Fistulizing Perianal Crohn's Disease Using Autologous Mesenchymal Stem Cells on a Dissolvable Matrix: Results from the Phase Ⅰ Stem Cell on Matrix Plug Trial[J]. Dis Colon Rectum, 2023, 66(2): 243-252. doi: 10.1097/DCR.0000000000002579
[34] Meyer J, Ris F, Parkes M, et al. Rectovaginal Fistula in Crohn's Disease: When and How to Operate?[J]. Clin Colon Rectal Surg, 2022, 35(1): 10-20. doi: 10.1055/s-0041-1740029
[35] 郭昭, 史学文. 脂肪来源间充质干细胞治疗克罗恩病肛瘘的研究进展[J]. 中国中西医结合消化杂志, 2023, 31(8): 654-658. doi: 10.3969/j.issn.1671-038X.2023.08.16
[36] Huang EY, Zhao B, Llaneras J, et al. Autologous fat grafting: an emerging treatment option for complex anal fistulas[J]. J Gastrointest Surg, 2023, 27(7): 1445-1453. doi: 10.1007/s11605-023-05719-4
[37] Nikolic M, Stift A, Reinisch W, et al. Allogeneic expanded adipose-derived stem cells in the treatment of rectovaginal fistulas in Crohn's disease[J]. Int J Colorectal Dis, 2021, 23(1): 153-158. doi: 10.1111/codi.15324
[38] Garcia-Olmo D, García-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy[J]. Int J Colorectal Dis, 2003, 18: 451-454. doi: 10.1007/s00384-003-0490-3
[39] Dige A, Hougaard HT, Agnholt J, et al. Efficacy of injection of freshly collected autologous adipose tissue into perianal fistulas in patients with Crohn's disease[J]. Gastroenterology, 2019, 156(8): 2208-2216. doi: 10.1053/j.gastro.2019.02.005
[40] De Gregorio M, Tiang T, Lee T, et al. Autologous fat graft injections for the treatment of perianal fistulas in Crohn's disease: a systematic review and single-arm meta-analysis[J]. ANZ J Surg, 2023, 93(5): 1162-1168. doi: 10.1111/ans.18231
[41] Panes J, Bouma G, Ferrante M, et al. INSPECT: a retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing Crohn's disease treated in the ADMIRE-CD trial[J]. Inflamm Bowel Dis, 2022, 28(11): 1737-1745. doi: 10.1093/ibd/izab361
[42] Panes J, Garcia-Olmo D, Van Assche G, et al. Long-term efficacy and safety of stem cell therapy(Cx601) for complex perianal fistulas in patients with Crohn's disease[J]. Gastroenterology, 2018, 154(5): 1334-1342. e4. doi: 10.1053/j.gastro.2017.12.020
[43] Zhou C, Li M, Zhang Y, et al. Autologous adipose-derived stem cells for the treatment of Crohn's fistula-in-ano: an open-label, controlled trial[J]. Stem Cell Res Ther, 2020, 11: 1-13. doi: 10.1186/s13287-019-1471-y
[44] Fathallah N, Akaffou M, Haouari MA, et al. Deep remission improves the quality of life of patients with Crohn's disease and anoperineal fistula treated with darvadstrocel: results of a French pilot study[J]. Tech Coloproctol, 2023, 27(12): 1201-1210. doi: 10.1007/s10151-023-02765-7
[45] Dave M, Dev A, Somoza RA, et al. Mesenchymal stem cells ameliorate inflammation in an experimental model of Crohn's disease via the mesentery[J]. bioRxiv, 2023, 2023.05.22.541829.
[46] Barnhoorn MC, Wasser MNJM, Roelofs H, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas[J]. J Crohns Colitis, 2020, 14(1): 64-70. doi: 10.1093/ecco-jcc/jjz116
[47] Lightner AL, Reese J, Ream J, et al. A Phase ⅠB/ⅡA Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease[J]. Dis Colon Rectum, 2023, 66(10): 1359-1372. doi: 10.1097/DCR.0000000000002567
[48] Otero-Pineiro AM, Lightner AL. Adult allogenic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease[J]. Tech Coloproctol, 2022, 26(10): 831-832. doi: 10.1007/s10151-022-02667-0
[49] Williams P, Klersy C, Karki C, et al. Mesenchymal stem cell therapy awareness, knowledge, and use for the treatment of fistulizing Crohn's disease: an International Survey Among Gastroenterologists and Colorectal surgeons[J]. Adv Ther, 2022, 39(6): 2761-2777. doi: 10.1007/s12325-022-02113-5
[50] Arkenbosch JHC, van Ruler O, Dwarkasing RS, et al. Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study[J]. Aliment Pharmacol Ther, 2023, 57(7): 783-791. doi: 10.1111/apt.17347
[51] Arkenbosch JHC, Becker MAJ, Buskens CJ, et al. Platelet-Rich stroma from Crohn's disease patients for treatment of perianal fistula shows a higher myeloid cell profile compared to non-IBD controls[J]. Stem Cell Res, 2023, 67: 103039. doi: 10.1016/j.scr.2023.103039
[52] Guillo L, Grimaud F, Houser F, et al. Three-year outcome of local injection of autologous stromal vascular fraction cells and microfat in refractory perianal fistulas of Crohn's disease[J]. Stem Cell Res, 2022, 13(1): 67.
-
计量
- 文章访问数: 234
- 施引文献: 0
下载: